Guest Editors
Jiatong Li
State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Dr J Jiatong Li earned her PhD, MD degree in Pharmacology in 2022, under the supervision of Prof. Bao-Feng Yang at Harbin Medical University (HMU). Subsequently, she joined the Shanghai Jiao Tong University School of Medicine in the same year, where her research endeavors primarily revolve around the advancement of novel antitumor therapeutics and the exploration of pharmacodynamics, drug actions, and underlying mechanisms. Eight SCI papers have been published in related fields, with a total impact factor of 73.6
Ao Gu
State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Department of Biliary-Pancreatic Surgery, Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai
Ao Gu received his MB degree in Clinical Medicine from Hebei University Health Science Center and is presently engaged in the pursuit of a doctoral degree at the Shanghai Jiao Tong University School of Medicine, under the mentorship of Professor Yingbin Liu. His research endeavors predominantly revolve around the investigation of the therapeutic capabilities exhibited by antitumor-active molecules. Six SCI papers have been published in related fields, with a total impact factor of 53.5
Collection Overview
In recent years, there has been a growing recognition of the limited relevance and reproducibility of cell lines and cell line-derived in vivo models in clinical studies. Consequently, a range of patient-derived in vivo and in vitro models, such as patient-derived xenografts (PDXs), patient-derived organoids (PDOs), tumor cell lines (PDCs), and patient-derived explants (PDEs), have emerged. These models have been well applied in basic and clinical medical research, offering a more accurate representation of tumor microenvironment heterogeneity, whether genetic or immunological.
This Methods Collection focuses on the construction, functional validation, and mechanistic understanding of patient-derived methods. Through this collection, we intend to present these experimental techniques in a highly accessible and comprehensible audio-visual format. We believe this will ultimately help advance the cancer research process and break the translation barriers from basic to clinical medical research.
Articles
Establishment of Tumor Organoids, Carcinoma-Associated Fibroblasts, and Counterpart Fibroblasts from the Same Esophageal Cancer Patient
0 Views
•
2026
•
Peining Zhang1,2, Tetsuo Kobayashi2,3, Motomi Nasu1, Tadasuke Hashiguchi1, Masaaki Abe2, Kazunari Yamashita2,3, Misaki Nomura2, Hajime Orita1, Tetsu Fukunaga1, Takashi Hashimoto1, Shinji Mine1, Akira Orimo2,3,4
1Department of Esophageal and Gastroenterological Surgery, Graduate School of Medicine, Juntendo University, 2Department of Molecular Pathogenesis, Graduate School of Medicine, Juntendo University, 3Department of Pathology and Oncology, Graduate School of Medicine, Juntendo University, 4Faculty of Health Sciences, Graduate School of Medicine, Juntendo University
Abstracts
A Protocol for Generating Patient Derived Organoid Models from Normal Colon, Primary and Metastatic Colorectal Cancer
Erdogan Oguzhan Akyildiz1,
Semir Beyaz*1
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States
A Protocol for Generating Patient Derived Organoid Models from Normal and Malignant Endometrium
Erdogan Oguzhan Akyildiz1,
Semir Beyaz*1
1Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States
A Protocol for Generating Patient Derived Organoid Models from Gastric Cancer
Tao Yu*1
1East China Normal Univerisity
Establishment of patient derived HCC cell lines
Xiaohui Wu*1,
Yuxi Li1
1The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital
Extraction and culture of patient-derived primary colorectal cancer tumour cells
Zeshuo Feng1
1Affiliated Zhongshan Hospital of Dalian University